Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CARDIOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-08-11
DOI
10.1016/j.amjcard.2022.07.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
- (2021) Salim S. Virani et al. CIRCULATION
- Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study
- (2021) Geert Goderis et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Reappraising the role of inflammation in heart failure
- (2020) Luigi Adamo et al. Nature Reviews Cardiology
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Practical Considerations and Rationale for GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes
- (2020) Ronald M. Goldenberg et al. Canadian Journal of Diabetes
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Benefit–risk review of different drug classes used in chronic heart failure
- (2018) Gabriela Andries et al. Expert Opinion On Drug Safety
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neurohormonal activation in heart failure with reduced ejection fraction
- (2016) Justin Hartupee et al. Nature Reviews Cardiology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- A systematic review identifies valid comorbidity indices derived from administrative health data
- (2015) Marko Yurkovich et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection
- (2013) Ting C Zhao Cardiovascular Diabetology
- Systematic Review of Comorbidity Indices for Administrative Data
- (2012) Mansour T. A. Sharabiani et al. MEDICAL CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search